NeuroBo Pharmaceuticals | Investor Presentation Deck | 27 slides

NeuroBo Pharmaceuticals · 2021-03
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

27
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
inspire_vision
04
summarize
05
The slide uses a horizontal bar chart format to represent the progression of drug candidates through clinical trial phases.plan_implementation
06
other
Open slide detailBeat · Team
07
The slide highlights the academic and professional credentials of the advisors to establish credibility.other
Open slide detailBeat · Team
08
transition
09
establish_context
Open slide detailBeat · Problem
10
present_solution
Open slide detailBeat · Problem
11
The diagram is a phylogenetic tree showing viral relationships.present_solution
Open slide detailBeat · Solution
12
The slide presents six distinct dose-response curves comparing Niclosamide against other agents like Remdesivir and Chloroquine.analyze_data
Open slide detailBeat · Solution
13
Includes a timeline diagram of the experimental procedure and a bar chart showing fold change in viral genome equivalents.present_solution
Open slide detailBeat · Solution
14
transition
15
The slide uses a 'COMPLETED' stamp overlay to indicate status.show_traction
16
The slide outlines a randomized controlled trial structure with specific timelines and patient criteria.plan_implementation
17
The table lists 10 distinct clinical trial entries.compare_peers
18
The slide uses a horizontal arrow-based timeline format.plan_implementation
19
transition
Open slide detailLoop · Why Now
20
The slide uses a Venn-like overlapping circle diagram to represent market segments.size_opportunity
Open slide detailBeat · Market SizeLoop · Why Now
21
establish_context
Open slide detailBeat · Market SizeLoop · Cost Of Inaction
22
Uses news clippings to validate market interest in COVID-19 therapeutics.cite_precedent
Open slide detailLoop · Cost Of Inaction
23
transition
24
Explains the 505(b)(2) pathway and associated market exclusivity.appendix
25
analyze_data
26
plan_implementation
27
state_next_steps